Angiogenesis and arteriogenesis as stroke targets

Translational Stroke Research: From Target Selection to Clinical Trials

Volumn , Issue , 2012, Pages 231-249

  Chen, Jieli ^a   Chopp, Michael ^a,b  

^a HENRY FORD HOSPITAL   (United States)

^b OAKLAND UNIVERSITY   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

EID: 84893755772     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-1-4419-9530-8_11     Document Type: Chapter

References (170)

1. Cronin CA. Intravenous tissue plasminogen activator for stroke: a review of the ECASS III results in relation to prior clinical trials. J Emerg Med. 2010;38(1):99-105.
2. Carpenter CR, et al. Thrombolytic therapy for acute ischemic stroke beyond three hours. J Emerg Med. 2011;40(1):82-92.
3. Katzan IL, et al. Utilization of intravenous tissue plasminogen activator for acute ischemic stroke. Arch Neurol. 2004;61(3):346-50.
4. Weimar C, et al. Intravenous thrombolysis in German stroke units before and after regulatory approval of recombinant tissue plasminogen activator. Cerebrovasc Dis. 2006;22(5-6): 429-31.
5. Schwammenthal Y, et al. Trombolysis in acute stroke. Isr Med Assoc J. 2006;8(11):784-7.
6. Pratt PF, Medhora M, Harder DR. Mechanisms regulating cerebral blood flow as therapeutic targets. Curr Opin Investig Drugs. 2004;5(9):952-6.
7. Plate KH. Mechanisms of angiogenesis in the brain. J Neuropathol Exp Neurol. 1999;58(4): 313-20.
8. Renner O, et al. Time- and cell type-specific induction of platelet-derived growth factor receptor-beta during cerebral ischemia. Brain Res Mol Brain Res. 2003;113(1-2):44-51.
9. Chen J, et al. Intravenous administration of human bone marrow stromal cells induces angiogenesis in the ischemic boundary zone after stroke in rats. Circ Res. 2003;92(6):692-9.
10. Krupinski J, et al. Role of angiogenesis in patients with cerebral ischemic stroke. Stroke. 1994;25(9): 1794-8.
11. Wei L, et al. Collateral growth and angiogenesis around cortical stroke. Stroke. 2001;32(9): 2179-84.
12. Christoforidis GA, et al. Angiographic assessment of pial collaterals as a prognostic indicator following intra-arterial thrombolysis for acute ischemic stroke. AJNR Am J Neuroradiol. 2005;26(7): 1789-97.
13. Liebeskind DS. Collaterals in acute stroke: beyond the clot. Neuroimaging Clin N Am. 2005;15(3):553-73
14. Dor Y, Keshet E. Ischemia-driven angiogenesis. Trends Cardiovasc Med. 1997;7(8):289-94.
15. Risau W. Mechanisms of angiogenesis. Nature. 1997;386(6626):671-4.
16. Folkman J, D'Amore PA. Blood vessel formation: what is its molecular basis? Cell. 1996;87(7):1153-5.
17. Patan S. Vasculogenesis and angiogenesis. Cancer Treat Res. 2004;117:3-32.
18. Schaper W, Buschmann I. Arteriogenesis, the good and bad of it. Eur Heart J. 1999;20(18): 1297-9.
19. Buschmann I, Schaper W. Arteriogenesis versus angiogenesis: two mechanisms of vessel growth. News Physiol Sci. 1999;14:121-5.
20. Scholz D, Cai WJ, Schaper W. Arteriogenesis, a new concept of vascular adaptation in occlusive disease. Angiogenesis. 2001;4(4):247-57.
21. Buschmann I, Schaper W. The pathophysiology of the collateral circulation (arteriogenesis). J Pathol. 2000;190(3):338-42.
22. van Royen N, et al. Stimulation of arteriogenesis; a new concept for the treatment of arterial occlusive disease. Cardiovasc Res. 2001;49(3):543-53.
23. Seetharam D, et al. High-density lipoprotein promotes endothelial cell migration and reendothelialization via scavenger receptor-B type I. Circ Res. 2006;98(1):63-72.
24. Heil M, Schaper W. Influence of mechanical, cellular, and molecular factors on collateral artery growth (arteriogenesis). Circ Res. 2004;95(5):449-58.
25. Jalali S, et al. Integrin-mediated mechanotransduction requires its dynamic interaction with specific extracellular matrix (ECM) ligands. Proc Natl Acad Sci USA. 2001;98(3):1042-6.
26. Cai WJ, et al. Activation of the integrins alpha 5beta 1 and alpha v beta 3 and focal adhesion kinase (FAK) during arteriogenesis. Mol Cell Biochem. 2009;322(1-2):161-9.
27. Chen KD, et al. Mechanotransduction in response to shear stress. Roles of receptor tyrosine kinases, integrins, and Shc. J Biol Chem. 1999;274(26):18393-400.
28. Chachisvilis M, Zhang YL, Frangos JA. G protein-coupled receptors sense fluid shear stress in endothelial cells. Proc Natl Acad Sci USA. 2006;103(42):15463-8.
29. Hoefer IE, et al. Arteriogenesis proceeds via ICAM-1/Mac-1- mediated mechanisms. Circ Res. 2004;94(9):1179-85.
30. Behm CZ, et al. Molecular imaging of endothelial vascular cell adhesion molecule-1 expression and inflammatory cell recruitment during vasculogenesis and ischemia-mediated arteriogenesis. Circulation. 2008;117(22):2902-11.
31. Hoefer IE, et al. Direct evidence for tumor necrosis factor-alpha signaling in arteriogenesis. Circulation. 2002;105(14):1639-41.
32. Kosaki K, et al. Fluid shear stress increases the production of granulocyte-macrophage colony-stimulating factor by endothelial cells via mRNA stabilization. Circ Res. 1998;82(7):794-802.
33. Buschmann IR, et al. GM-CSF: a strong arteiiogenic factor acting by amplification of monocyte function. Atherosclerosis. 2001;159(2):343-56.
34. Cai WJ, et al. Expression of endothelial nitric oxide synthase in the vascular wall during arteriogenesis. Mol Cell Biochem. 2004;264(1-2):193-200.
35. Arras M, et al. Monocyte activation in angiogenesis and collateral growth in the rabbit hindlimb. J Clin Invest. 1998;101(1):40-50.
36. Schaper W, Scholz D. Factors regulating arteriogenesis. Arterioscler Thromb Vasc Biol. 2003;23(7): 1143-51.
37. Suri C, et al. Requisite role of angiopoietin-1, a ligand for the TIE2 receptor, during embryonic angiogenesis. Cell. 1996;87(7):1171-80.
38. Pfaff D, Fiedler U, Augustin HG. Emerging roles of the Angiopoietin-Tie and the ephrin-Eph systems as regulators of cell trafficking. J Leukoc Biol. 2006;80(4):719-26.
39. Marti HH, Risau W. Angiogenesis in ischemic disease. Thromb Haemost. 1999;82 Suppl 1:44-52.
40. Nourhaghighi N, et al. Altered expression of angiopoietins during blood-brain barrier breakdown and angiogenesis. Lab Invest. 2003;83(8):1211-22.
41. Maisonpierre PC, et al. Angiopoietin-2, a natural antagonist for Tie2 that disrupts in vivo angiogenesis. Science. 1997;277(5322):55-60.
42. Tammela T, et al. Angiopoietin-1 promotes lymphatic sprouting and hyperplasia. Blood. 2005;105(12):4642-8.
43. Mochizuki Y, et al. Angiopoietin 2 stimulates migration and tube-like structure formation of murine brain capillary endothelial cells through c-Fes and c-Fyn. J Cell Sci. 2002;115(Pt 1): 175-83.
44. Nag S, Kapadia A, Stewart DJ. Review: molecular pathogenesis of blood-brain barrier breakdown in acute brain injury. Neuropathol Appl Neurobiol. 2011;37(1):3-23.
45. Hori S, et al. A pericyte-derived angiopoietin-1 multimeric complex induces occludin gene expression in brain capillary endothelial cells through Tie-2 activation in vitro. J Neurochem. 2004;89(2):503-13.
46. Iurlaro M, et al. Rat aorta-derived mural precursor cells express the Tie2 receptor and respond directly to stimulation by angiopoietins. J Cell Sci. 2003;116(Pt 17):3635-43.
47. Suri C, et al. Increased vascularization in mice overexpressing angiopoietin-1. Science. 1998;282(5388):468-71.
48. Zhang ZG, et al. Angiopoietin-1 reduces cerebral blood vessel leakage and ischemic lesion volume after focal cerebral embolic ischemia in mice. Neuroscience. 2002;113(3):683-7.
49. Thurston G, et al. Angiopoietin-1 protects the adult vasculature against plasma leakage. Nat Med. 2000;6(4):460-3.
50. Shim WS, et al. Angiopoietin-1 promotes functional neovascularization that relieves ischemia by improving regional reperfusion in a swine chronic myocardial ischemia model. J Biomed Sci. 2006;13(4):579-91.
51. Shyu KG, et al. Direct intramuscular injection of plasmid DNA encoding angiopoietin-1 but not angiopoietin-2 augments revascularization in the rabbit ischemic hindlimb. Circulation. 1998;98(19):2081-7.
52. Chae JK, et al. Coadministration of angiopoietin-1 and vascular endothelial growth factor enhances collateral vascularization. Arterioscler Thromb Vasc Biol. 2000;20(12):2573-8.
53. Siddiqui AJ, et al. Combination of angiopoietin-1 and vascular endothelial growth factor gene therapy enhances arteriogenesis in the ischemic myocardium. Biochem Biophys Res Commun. 2003;310(3):1002-9.
54. Namiecinska M, Marciniak K, Nowak JZ. VEGF as an angiogenic, neurotrophic, and neuroprotective factor. Postepy Hig Med Dosw (Online). 2005;59:573-83.
55. Ortega N, Hutchings H, Plouet J. Signal relays in the VEGF system. Front Biosci. 1999;4:D141-52.
56. Zhang Z, et al. VEGF-dependent tumor angiogenesis requires inverse and reciprocal regulation of VEGFR1 and VEGFR2. Cell Death Differ. 2010;17(3):499-512.
57. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med. 2003;9(6):669-76.
58. Hess AP, et al. Expression of the vascular endothelial growth factor receptor neuropilin-1 in the human endometrium. J Reprod Immunol. 2009;79(2):129-36.
59. Banerjee S, et al. VEGF-A165 induces human aortic smooth muscle cell migration by activating neuropilin-1-VEGFR1-PI3K axis. Biochemistry. 2008;47(11):3345-51.
60. Zhang ZG, et al. VEGF enhances angiogenesis and promotes blood-brain barrier leakage in the ischemic brain. J Clin Invest. 2000;106(7):829-38.
61. Manoonkitiwongsa PS, et al. Contraindications of VEGF-based therapeutic angiogenesis: effects on macrophage density and histology of normal and ischemic brains. Vascul Pharmacol. 2006;44(5):316-25.
62. Satchell SC, Anderson KL, Mathieson PW. Angiopoietin 1 and vascular endothelial growth factor modulate human glomerular endothelial cell barrier properties. J Am Soc Nephrol. 2004;15(3):566-74.
63. Valable S, et al. VEGF-induced BBB permeability is associated with an MMP-9 activity increase in cerebral ischemia: both effects decreased by Ang-1. J Cereb Blood Flow Metab. 2005;25(11): 1491-504.
64. Hattori K, et al. Vascular endothelial growth factor and angiopoietin-1 stimulate postnatal hematopoiesis by recruitment of vasculogenic and hematopoietic stem cells. J Exp Med. 2001;193(9): 1005-14.
65. Gluzman Z, et al. Endothelial cells are activated by angiopoeitin-1 gene transfer and produce coordinated sprouting in vitro and arteriogenesis in vivo. Biochem Biophys Res Commun. 2007;359(2):263-8.
66. Lee PC, et al. Impaired wound healing and angiogenesis in eNOS-deficient mice. Am J Physiol. 1999;277(4 Pt 2):H1600-8.
67. Yu J, et al. Endothelial nitric oxide synthase is critical for ischemic remodeling, mural cell recruitment, and blood flow reserve. Proc Natl Acad Sci USA. 2005;102(31):10999-1004.
68. Jozkowicz A, et al. Genetic augmentation of nitric oxide synthase increases the vascular generation of VEGF. Cardiovasc Res. 2001;51(4):773-83.
69. Rudic RD, et al. Direct evidence for the importance of endothelium-derived nitric oxide in vascular remodeling. J Clin Invest. 1998;101(4):731-6.
70. Murohara T, et al. Nitric oxide synthase modulates angiogenesis in response to tissue ischemia. J Clin Invest. 1998;101(11):2567-78.
71. Lopez-Farre A, et al. Role of nitric oxide in the control of apoptosis in the microvasculature. Int J Biochem Cell Biol. 1998;30(10):1095-106.
72. Lee PC, et al. Nitric oxide induces angiogenesis and upregulates alpha(v)beta(3) integrin expression on endothelial cells. Microvasc Res. 2000;60(3):269-80.
73. Dulak J, et al. Nitric oxide induces the synthesis of vascular endothelial growth factor by rat vascular smooth muscle cells. Arterioscler Thromb Vasc Biol. 2000;20(3):659-66.
74. Ziche M, et al. Nitric oxide promotes proliferation and plasminogen activator production by coronary venular endothelium through endogenous bFGF. Circ Res. 1997;80(6):845-52.
75. Michel JB. Role of endothelial nitric oxide in the regulation of the vasomotor system. Pathol Biol (Paris). 1998;46(3):181-9.
76. Kaur S, et al. Genetic engineering with endothelial nitric oxide synthase improves functional properties of endothelial progenitor cells from patients with coronary artery disease: an in vitro study. Basic Res Cardiol. 2009;104(6):739-49.
77. Yang HT, et al. Prior exercise training produces NO-dependent increases in collateral blood flow after acute arterial occlusion. Am J Physiol Heart Circ Physiol. 2002;282(1):H301-10.
78. Michel JB. Role of endothelial nitric oxide in the regulation of arterial tone. Rev Prat. 1997;47(20):2251-6.
79. Fulton D, et al. Regulation of endothelium-derived nitric oxide production by the protein kinase Akt. Nature. 1999;399(6736):597-601.
80. Dai X, Faber JE. Endothelial nitric oxide synthase deficiency causes collateral vessel rarefaction and impairs activation of a cell cycle gene network during arteriogenesis. Circ Res. 2010;106(12): 1870-81.
81. Brevetti LS, et al. Overexpression of endothelial nitric oxide synthase increases skeletal muscle blood flow and oxygenation in severe rat hind limb ischemia. J Vasc Surg. 2003;38(4): 820-6.
82. Prior BM, et al. Arteriogenesis: role of nitric oxide. Endothelium. 2003;10(4-5):207-16.
83. Gertz K, et al. Physical activity improves long-term stroke outcome via endothelial nitric oxide synthase-dependent augmentation of neovascularization and cerebral blood flow. Circ Res. 2006;99(10):1132-40.
84. Cramer SC, Chopp M. Recovery recapitulates ontogeny. Trends Neurosci. 2000;23(6):265-71.
85. Landers M. Treatment-induced neuroplasticity following focal injury to the motor cortex. Int J Rehabil Res. 2004;27(1):1-5.
86. Cairns K, Finklestein SP. Growth factors and stem cells as treatments for stroke recovery. Phys Med Rehabil Clin N Am. 2003;14(1 Suppl):S135-42.
87. Hurtado O, et al. Neurorepair versus neuroprotection in stroke. Cerebrovasc Dis. 2006;21 Suppl 2:54-63.
88. Jacobson TA. Overcoming 'ageism' bias in the treatment of hypercholesterolaemia: a review of safety issues with statins in the elderly. Drug Saf. 2006;29(5):421-48.
89. Moonis M, et al. HMG-CoA reductase inhibitors improve acute ischemic stroke outcome. Stroke. 2005;36(6):1298-300.
90. Skaletz-Rorowski A, Walsh K. Statin therapy and angiogenesis. Curr Opin Lipidol. 2003;14(6):599-603.
91. Chen J, et al. Vascular endothelial growth factor mediates atorvastatin-induced mammalian achaete-scute homologue-1 gene expression and neuronal differentiation after stroke in retired breeder rats. Neuroscience. 2006;141(2):737-44.
92. Chen J, et al. Statins induce angiogenesis, neurogenesis, and synaptogenesis after stroke. Ann Neurol. 2003;53(6):743-51.
93. Sata M, et al. Statins augment collateral growth in response to ischemia but they do not promote cancer and atherosclerosis. Hypertension. 2004;43(6):1214-20.
94. Skaletz-Rorowski A, et al. The pro- and antiangiogenic effects of statins. Semin Vasc Med. 2004;4(4):395-400.
95. Urbich C, et al. Double-edged role of statins in angiogenesis signaling. Circ Res. 2002;90(6):737-44.
96. Walter DH, et al. Statin therapy accelerates reendothelialization: a novel effect involving mobilization and incorporation of bone marrow-derived endothelial progenitor cells. Circulation. 2002;105(25):3017-24.
97. Liao JK. Clinical implications for statin pleiotropy. Curr Opin Lipidol. 2005;16(6):624-9.
98. Chen J, et al. Atorvastatin induction of VEGF and BDNF promotes brain plasticity after stroke in mice. J Cereb Blood Flow Metab. 2005;25(2):281-90.
99. Dimmeler S, et al. HMG-CoA reductase inhibitors (statins) increase endothelial progenitor cells via the PI 3-kinase/Akt pathway. J Clin Invest. 2001;108(3):391-7.
100. Maeda T, Kawane T, Horiuchi N. Statins augment vascular endothelial growth factor expression in osteoblastic cells via inhibition of protein prenylation. Endocrinology. 2003;144(2):681-92.
101. Walter DH, Zeiher AM, Dimmeler S. Effects of statins on endothelium and their contribution to neovascularization by mobilization of endothelial progenitor cells. Coron Artery Dis. 2004;15(5):235-42.
102. Kureishi Y, et al. The HMG-CoA reductase inhibitor simvastatin activates the protein kinase Akt and promotes angiogenesis in normocholesterolemic animals. Nat Med. 2000;6(9):1004-10.
103. Khaidakov M, et al. Statins and angiogenesis: is it about connections? Biochem Biophys Res Commun. 2009;387(3):543-7.
104. Zacharek A, et al. Simvastatin increases notch signaling activity and promotes arteriogenesis after stroke. Stroke. 2009;40(1):254-60.
105. Lakhan SE, Bagchi S, Hofer M. Statins and clinical outcome of acute ischemic stroke: a systematic review. Int Arch Med. 2010;3:22.
106. Matsumura M, et al. Effects of atorvastatin on angiogenesis in hindlimb ischemia and endothelial progenitor cell formation in rats. J Atheroscler Thromb. 2009;16(4):319-26.
107. Llevadot J, et al. HMG-CoA reductase inhibitor mobilizes bone marrow-derived endothelial progenitor cells. J Clin Invest. 2001;108(3):399-405.
108. Dimmeler S, Dernbach E, Zeiher AM. Phosphorylation of the endothelial nitric oxide synthase at ser-1177 is required for VEGF-induced endothelial cell migration. FEBS Lett. 2000;477(3):258-62.
109. Vasa M, et al. Increase in circulating endothelial progenitor cells by statin therapy in patients with stable coronary artery disease. Circulation. 2001;103(24):2885-90.
110. Newman GC, et al. Association of diabetes, homocysteine, and HDL with cognition and disability after stroke. Neurology. 2007;69(22):2054-62.
111. Sanossian N, et al. Do high-density lipoprotein cholesterol levels influence stroke severity? J Stroke Cerebrovasc Dis. 2006;15(5):187-9.
112. van Exel E, et al. Association between high-density lipoprotein and cognitive impairment in the oldest old. Ann Neurol. 2002;51(6):716-21.
113. Tanne D, Yaari S, Goldbourt U. High-density lipoprotein cholesterol and risk of ischemic stroke mortality. A 21-year follow-up of 8586 men from the Israeli Ischemic heart disease study. Stroke. 1997;28(1):83-7.
114. Zivkovic SA, et al. Rapidly progressive stroke in a young adult with very low high-density lipoprotein cholesterol. J Neuroimaging. 2000;10(4):233-6.
115. Corti MC, et al. HDL cholesterol predicts coronary heart disease mortality in older persons. JAMA. 1995;274(7):539-44.
116. Weverling-Rijnsburger AW, et al. High-density vs low-density lipoprotein cholesterol as the risk factor for coronary artery disease and stroke in old age. Arch Intern Med. 2003;163(13): 1549-54.
117. Mineo C, et al. Endothelial and antithrombotic actions of HDL. Circ Res. 2006;98(11):1352-64.
118. Kuvin JT, et al. A novel mechanism for the beneficial vascular effects of high-density lipoprotein cholesterol: enhanced vasorelaxation and increased endothelial nitric oxide synthase expression. Am Heart J. 2002;144(1):165-72.
119. Mineo C, et al. High density lipoprotein-induced endothelial nitric-oxide synthase activation is mediated by Akt and MAP kinases. J Biol Chem. 2003;278(11):9142-9.
120. Assanasen C, et al. Cholesterol binding, efflux, and a PDZ-interacting domain of scavenger receptor-BI mediate HDL-initiated signaling. J Clin Invest. 2005;115(4):969-77.
121. Nofer JR, et al. HDL induces NO-dependent vasorelaxation via the lysophospholipid receptor S1P3. J Clin Invest. 2004;113(4):569-81.
122. Pu DR, Liu L. HDL slowing down endothelial progenitor cells senescence: a novel antiatherogenic property of HDL. Med Hypotheses. 2008;70(2):338-42.
123. Zhang Q, et al. Essential role of HDL on endothelial progenitor cell proliferation with PI3K/Akt/cyclin D1 as the signal pathway. Exp Biol Med (Maywood). 2010;235(9): 1082-92.
124. Sumi M, et al. Reconstituted high-density lipoprotein stimulates differentiation of endothelial progenitor cells and enhances ischemia-induced angiogenesis. Arterioscler Thromb Vasc Biol. 2007;27(4):813-8.
125. Elam MB, et al. Effect of niacin on lipid and lipoprotein levels and glycemic control in patients with diabetes and peripheral arterial disease: the ADMIT study: a randomized trial. Arterial disease multiple intervention trial. JAMA. 2000;284(10):1263-70.
126. Schachter M. Strategies for modifying high-density lipoprotein cholesterol: a role for nicotinic acid. Cardiovasc Drugs Ther. 2005;19(6):415-22.
127. Shepherd J, Betteridge J, Van Gaal L. Nicotinic acid in the management of dyslipidaemia associated with diabetes and metabolic syndrome: a position paper developed by a European Consensus Panel. Curr Med Res Opin. 2005;21(5):665-82.
128. Kamanna VS, Kashyap ML. Mechanism of action of niacin. Am J Cardiol. 2008;101(8A): 20B-6.
129. Jin FY, Kamanna VS, Kashyap ML. Niacin accelerates intracellular ApoB degradation by inhibiting triacylglycerol synthesis in human hepatoblastoma (HepG2) cells. Arterioscler Thromb Vasc Biol. 1999;19(4):1051-9.
130. Jin FY, Kamanna VS, Kashyap ML. Niacin decreases removal of high-density lipoprotein apolipoprotein A-I but not cholesterol ester by Hep G2 cells. Implication for reverse cholesterol transport. Arterioscler Thromb Vasc Biol. 1997;17(10):2020-8.
131. Rosenson RS. Antiatherothrombotic effects of nicotinic acid. Atherosclerosis. 2003;171(1):87-96.
132. Chen J, et al. Niaspan increases angiogenesis and improves functional recovery after stroke. Ann Neurol. 2007;62(1):49-58.
133. Chen J, et al. Niaspan treatment increases tumor necrosis factor-alpha-converting enzyme and promotes arteriogenesis after stroke. J Cereb Blood Flow Metab. 2009;29(5):911-20.
134. Chapman MJ. Therapeutic elevation of HDL-cholesterol to prevent atherosclerosis and coronary heart disease. Pharmacol Ther. 2006;111(3):893-908.
135. Toth PP. High-density lipoprotein as a therapeutic target: clinical evidence and treatment strategies. Am J Cardiol. 2005;96(9A):50K-8K; discussion 34K-5K.
136. Grundmann S, et al. Anti-tumor necrosis factor-(alpha) therapies attenuate adaptive arteriogenesis in the rabbit. Am J Physiol Heart Circ Physiol. 2005;289(4):H1497-505.
137. Edwards DR, Handsley MM, Pennington CJ. The ADAM metalloproteinases. Mol Aspects Med. 2008;29(5):258-89.
138. Garton KJ, et al. Stimulated shedding of vascular cell adhesion molecule 1 (VCAM-1) is mediated by tumor necrosis factor-alpha-converting enzyme (ADAM 17). J Biol Chem. 2003;278(39):37459-64.
139. Krause DS. Plasticity of marrow-derived stem cells. Gene Ther. 2002;9(11):754-8.
140. Menasche P. Cell transplantation for the treatment of heart failure. Semin Thorac Cardiovasc Surg. 2002;14(2):157-66.
141. Wang JS, et al. Marrow stromal cells for cellular cardiomyoplasty: feasibility and potential clinical advantages. J Thorac Cardiovasc Surg. 2000;120(5):999-1005.
142. Chen J, et al. Therapeutic benefit of intracerebral transplantation of bone marrow stromal cells after cerebral ischemia in rats. J Neurol Sci. 2001;189(1-2):49-57.
143. Li Y, et al. Human marrow stromal cell therapy for stroke in rat: neurotrophins and functional recovery. Neurology. 2002;59(4):514-23.
144. Chen J, et al. Therapeutic benefit of intravenous administration of bone marrow stromal cells after cerebral ischemia in rats. Stroke. 2001;32(4):1005-11.
145. Wu J, et al. Intravenously administered bone marrow cells migrate to damaged brain tissue and improve neural function in ischemic rats. Cell Transplant. 2008;16(10):993-1005.
146. Riess P, et al. Transplanted neural stem cells survive, differentiate, and improve neurological motor function after experimental traumatic brain injury. Neurosurgery. 2002;51(4):1043-52; discussion 1052-4.
147. Sanchez-Ramos J, et al. Adult bone marrow stromal cells differentiate into neural cells in vitro. Exp Neurol. 2000;164(2):247-56.
148. Tang YL, et al. Paracrine action enhances the effects of autologous mesenchymal stem cell transplantation on vascular regeneration in rat model of myocardial infarction. Ann Thorac Surg. 2005;80(1):229-36; discussion 236-7.
149. Kinnaird T, et al. Bone marrow-derived cells for enhancing collateral development: mechanisms, animal data, and initial clinical experiences. Circ Res. 2004;95(4):354-63.
150. Ponte AL, et al. The in vitro migration capacity of human bone marrow mesenchymal stem cells: comparison of chemokine and growth factor chemotactic activities. Stem Cells. 2007;25(7): 1737-45.
151. Wu Y, et al. Mesenchymal stem cells enhance wound healing through differentiation and angiogenesis. Stem Cells. 2007;25(10):2648-59.
152. Kinnaird T, et al. Marrow-derived stromal cells express genes encoding a broad spectrum of arteriogenic cytokines and promote in vitro and in vivo arteriogenesis through paracrine mechanisms. Circ Res. 2004;94(5):678-85.
153. Matsuda-Hashii Y, et al. Hepatocyte growth factor plays roles in the induction and autocrine maintenance of bone marrow stromal cell IL-11, SDF-1 alpha, and stem cell factor. Exp Hematol. 2004;32(10):955-61.
154. Annabi B, et al. Hypoxia promotes murine bone-marrow-derived stromal cell migration and tube formation. Stem Cells. 2003;21(3):337-47.
155. Zacharek A, et al. Angiopoietin1/Tie2 and VEGF/Flk1 induced by MSC treatment amplifies angiogenesis and vascular stabilization after stroke. J Cereb Blood Flow Metab. 2007;27(10): 1684-91.
156. Chen J, et al. Intravenous bone marrow stromal cell therapy reduces apoptosis and promotes endogenous cell proliferation after stroke in female rat. J Neurosci Res. 2003;73(6):778-86.
157. Al-Khaldi A, et al. Postnatal bone marrow stromal cells elicit a potent VEGF-dependent neoangiogenic response in vivo. Gene Ther. 2003;10(8):621-9.
158. Al-Khaldi A, et al. Therapeutic angiogenesis using autologous bone marrow stromal cells: improved blood flow in a chronic limb ischemia model. Ann Thorac Surg. 2003;75(1):204-9.
159. Cui X, et al. Chemokine, vascular and therapeutic effects of combination Simvastatin and BMSC treatment of stroke. Neurobiol Dis. 2009;36(1):35-41.
160. Eaves CJ, et al. Mechanisms that regulate the cell cycle status of very primitive hematopoietic cells in long-term human marrow cultures. II. Analysis of positive and negative regulators produced by stromal cells within the adherent layer. Blood. 1991;78(1):110-7.
161. Majumdar MK, et al. Phenotypic and functional comparison of cultures of marrow-derived mesenchymal stem cells (MSCs) and stromal cells. J Cell Physiol. 1998;176(1):57-66.
162. Seshi B, Kumar S, Sellers D. Human bone marrow stromal cell: coexpression of markers specific for multiple mesenchymal cell lineages. Blood Cells Mol Dis. 2000;26(3):234-46.
163. Bang OY, et al. Autologous mesenchymal stem cell transplantation in stroke patients. Ann Neurol. 2005;57(6):874-82.
164. Sykova E, et al. Bone marrow stem cells and polymer hydrogels-two strategies for spinal cord injury repair. Cell Mol Neurobiol. 2006;26(7-8):1113-29.
165. Malgieri A, et al. Bone marrow and umbilical cord blood human mesenchymal stem cells: state of the art. Int J Clin Exp Med. 2010;3(4):248-69.
166. Suarez-Monteagudo C, et al. Autologous bone marrow stem cell neurotransplantation in stroke patients. An open study. Restor Neurol Neurosci. 2009;27(3):151-61.
167. Lee JS, et al. A long-term follow-up study of intravenous autologous mesenchymal stem cell transplantation in patients with ischemic stroke. Stem Cells. 2010;28(6):1099-106.
168. Chen J, et al. Intravenous administration of human umbilical cord blood reduces behavioral deficits after stroke in rats. Stroke. 2001;32(11):2682-8.
169. Newcomb JD, et al. Timing of cord blood treatment after experimental stroke determines therapeutic efficacy. Cell Transplant. 2006;15(3):213-23.
170. Zhang L, et al. Delayed administration of human umbilical tissue-derived cells improved neurological functional recovery in a rodent model of focal ischemia. Stroke. 2011;42(5): 1437-44.